Pregnane X receptor mediates Sorafenib resistance in advanced hepatocellular carcinoma.

Author
:
F Feng
Q Jiang
S Cao
Y Cao
R Li
L Shen
H Zhu
T Wang
L Sun
E Liang
H Sun
Y Chai
X Li
G Liu
R Yang
Z Yang
Y Yang
S Xin
BA Li
Abstract
:

Kinase inhibitor sorafenib is the most widely used drug for advanced HCC clinical treatment nowadays. However, sorafenib administration is only effective for a small portion of HCC patients, and the majority develop sorafenib-resistance during treatment. Thus, it is urgent to discover the endogenous mechanism and identify new pharmaceutical targets of sorafenib-resistance.
Year of Publication
:
2018
Journal
:
Biochimica et biophysica acta
Date Published
:
2018
ISSN Number
:
0006-3002
URL
:
http://linkinghub.elsevier.com/retrieve/pii/S0304-4165(18)30016-3
DOI
:
10.1016/j.bbagen.2018.01.011
Short Title
:
Biochim Biophys Acta
Download citation